spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bivalirudin 

 HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel
 HSMN NewsFeed - 1 Sep 2016
FDA Approves New AGGRASTAT(R) Product Format
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 12 Jul 2016
Federal Circuit Rules for The Medicines Company in Angiomax(R) (bivalirudin) Patent Litigation
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 11 May 2016
Medicure Files Application for New AGGRASTAT(R) Product Format
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 4 Feb 2016
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Oct 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Biopharmaceuticals Interventional
 HSMN NewsFeed - 12 Dec 2012
The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Aug 2012
Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Oct 2011
The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With Teva
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2010
The Medicines Company Files Additional Patent Infringement Lawsuits
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Dec 2009
The Medicines Company Acquires ApoA-I Milano From Pfizer
Biopharmaceuticals Licening
 HSMN NewsFeed - 1 Dec 2009
The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 2 Oct 2009
The Medicines Company Announces the Resignation of Its Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2009
The Medicines Company Responds to Incorrect News Reports
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Jul 2009
The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2009
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Feb 2009
The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2009
The Medicines Company to Acquire Targanta Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2008
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
TVM Capital Welcomes The Medicines Company in The European Market Through the Acquisition of Curacyte Discovery GmbH
Biopharmaceuticals Venture Capital Mergers & Acquisitions
 HSMN NewsFeed - 4 Aug 2008
The Medicines Company's Cleviprex(TM) Receives FDA Approval
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2008
New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Jun 2008
Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Jun 2008
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2008
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 May 2008
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 4 Feb 2008
Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2008
The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 7 Jan 2008
James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2007
Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Oct 2007
Improved Perioperative Blood Pressure Control Associated with Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients
Biopharmaceuticals Cardiology Surgery
 HSMN NewsFeed - 24 Sep 2007
FDA Accepts sNDA for Expanded Use of Angiomax(R) (bivalirudin)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 14 Sep 2007
FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jul 2007
The Medicines Company Reacquires Angiox(R) (Bivalirudin) Rights in Europe from Nycomed
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Apr 2007
The Medicines Company Elects Hiroaki Shigeta to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
Pivotal Phase III Findings With Investigational Drug Cleviprex(TM) (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Mar 2007
Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
ACUITY One-Year Findings Meet All Primary Endpoints in Favor of Angiomax(R) (Bivalirudin) Alone Treatment Group
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Mar 2007
The Medicines Company Products Angiomax(R) (bivalirudin) and Cleviprex(TM) (clevidipine) Featured in Three Late Breaking Trials at American College of Cardiology Annual Scientific Session
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 Feb 2007
The Medicines Company Supports Landmark Patient Observational Study and Clinical Survey on Acute Severe Hypertension
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Jan 2007
The Medicines Company's Cleviprex(TM) (Clevidipine) Phase III Safety Trials Meet Pre-Specified Objectives
Biopharmaceuticals
 HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Oct 2006
The Medicines Company Commences Phase III Clinical Trial of Cangrelor
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 11 Sep 2006
The Medicines Company Completes Clevidipine Phase III Safety Trials and Initiates Phase III Severe Hypertension Trial
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 38

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 38 additional stories matching:
bivalirudin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.